These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 25518344

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Antisese oligonucleotide therapy for patients with castration-resistant prostate cancer].
    Muramaki M, Miyake H, Fujisawa M.
    Nihon Rinsho; 2016 May 20; 74 Suppl 3():234-7. PubMed ID: 27344734
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Gene therapy for castration resistant prostate cancer].
    Nasu Y.
    Nihon Rinsho; 2014 Dec 20; 72(12):2152-7. PubMed ID: 25518350
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I.
    Clin Sci (Lond); 2006 Apr 20; 110(4):427-42. PubMed ID: 16526947
    [Abstract] [Full Text] [Related]

  • 9. Molecular landscape of prostate cancer: implications for current clinical trials.
    Khemlina G, Ikeda S, Kurzrock R.
    Cancer Treat Rev; 2015 Nov 20; 41(9):761-6. PubMed ID: 26210103
    [Abstract] [Full Text] [Related]

  • 10. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar 20; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 11. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
    Le TK, Cherif C, Omabe K, Paris C, Lannes F, Audebert S, Baudelet E, Hamimed M, Barbolosi D, Finetti P, Bastide C, Fazli L, Gleave M, Bertucci F, Taïeb D, Rocchi P.
    Mol Ther; 2023 Feb 01; 31(2):471-486. PubMed ID: 35965411
    [Abstract] [Full Text] [Related]

  • 12. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 13. [Prospects for antisense therapy].
    Maekawa T.
    Rinsho Ketsueki; 1995 May 01; 36(5):410-8. PubMed ID: 7783344
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunotherapy in prostate cancer: challenges and opportunities.
    Noguchi M, Koga N, Moriya F, Itoh K.
    Immunotherapy; 2016 May 01; 8(1):69-77. PubMed ID: 26642100
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul 01; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY, Cheung E.
    Endocr Relat Cancer; 2014 Feb 01; 21(1):R1-R11. PubMed ID: 24152433
    [Abstract] [Full Text] [Related]

  • 20. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
    Yamanaka K, Gleave M, Muramaki M, Hara I, Miyake H.
    Oncol Rep; 2005 May 01; 13(5):885-90. PubMed ID: 15809754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.